The Board Chair and Lead Independent Director in a Clinical-Stage Biopharma
In a well-functioning large-cap public company, the question of who chairs the board is settled by long-standing convention. Either the CEO holds the chair role and a designated lead independent director provides the structural counterweight, or the chair is a fully independent director who has the time, the experience, and the authority to lead the board as an institution distinct from management. The convention is supported by listing standards that disclose the choice, by proxy advisors who push for separation, and by a deep bench of seasoned former executives who make their second careers as board chairs.
None of this applies cleanly to a clinical-stage biopharma. The CEO is typically the founder or a heavily-invested operating executive who does not have the time to also run the board as an institution. The investor directors who hold most of the non-CEO seats are paid to manage their funds, not to chair portfolio company boards. The independent directors are often part-time advisors who chose this particular board because they wanted a specific kind of engagement, which usually was not chairing the board.
The result, in many small biopharma companies, is that no one is actually running the board. The CEO sets the agenda by default. Board meetings happen because they have to. Executive sessions are perfunctory or skipped. The work that a chair should be doing — managing the board's composition, surfacing difficult conversations, ensuring that the relationship between the board and the CEO is healthy and productive — does not get done, because no one is responsible for doing it.
This article is about who should be doing that work, what it actually involves, and the choices a small biopharma board has when it considers the question seriously.
The Default Path and Why It Fails
The default path in venture-backed biopharma is for the lead investor to take the chair role. The reasoning is plausible: the lead investor has the largest economic stake outside management, has the most context on the company from the financing process, and has the relationships within the venture community that the company will need for follow-on financings and ultimately for an exit. Naming the lead investor as chair acknowledges this reality.
The problem is that the role of chair is not the same as the role of largest investor representative. The chair's job is to run the board as an institution that governs in the interests of the company and all of its shareholders. The investor director's job is to represent the interests of a specific fund. These two jobs overlap most of the time, but they diverge at exactly the moments that matter most — when the company is considering a transaction that the lead investor's fund would prefer to delay, when management compensation is being set, when a related-party transaction with another portfolio company is being negotiated, when the question is whether to take a partnership offer or hold out for an acquisition.
A lead investor who is also chair finds themselves wearing two hats in these moments, and the structural conflict is not resolvable by good intentions. The chair is supposed to lead the board through these decisions; the investor representative is supposed to advocate for their fund's position. Asking the same person to do both is asking them to argue with themselves in real time, in a meeting they are also running.
This is not a hypothetical concern. In most clinical-stage biopharma companies, the lead investor's exit timeline is driven by their fund's vintage. Funds that have held a position for seven years are differently motivated than funds that have held it for three. The board's interests — and the company's interests — are about getting the best outcome, not about hitting a particular fund's timeline. A chair who is also the lead investor is structurally compromised in any decision where these interests might diverge.
There is a softer version of the same problem when the chair role is held by a different investor director — not the lead investor, but a representative of another significant fund. The structural conflict is the same in form, even if the dynamics are different in detail. The chair role inevitably becomes a representational role, the agenda inevitably reflects the chairing fund's priorities, and the other directors inevitably calibrate their participation around that reality.
Independent Chair: The Hard Path That Usually Works
The alternative that produces the best governance outcomes, when it is achievable, is appointing a fully independent chair. This is not an easy alternative. It requires finding a director who has the time, the experience, and the relevant expertise to run the board, and who is willing to accept the role and the responsibility that comes with it. In a small biopharma, this is often the most difficult board recruitment the company will undertake.
The reason it is difficult is that the chair role in a small biopharma is more demanding than the chair role in a large-cap company, in proportion to the resources available. The chair manages the board agenda in coordination with the CEO. The chair leads executive sessions. The chair handles director recruitment and onboarding. The chair has the conversations with the CEO that other directors are not positioned to have. The chair represents the board to external parties — auditors, regulatory advisors, potential acquirers — when the relationship needs to be at the board level rather than the management level. In a company without a corporate secretary, the chair often functionally serves as one, ensuring that the board's documentary record is maintained.
The time commitment for an effective chair is meaningful — typically two to three times what a regular director invests, with significant spikes during periods of intense activity. The compensation, in equity-heavy structures typical of clinical-stage companies, may not justify this commitment for a candidate who has other options. The candidates who accept the role are usually those who have a particular interest in the company's mission, a personal relationship with the CEO or the lead investor, or an explicit understanding that the role is a stepping stone toward something else — a future board position at a larger company, an advisory role with an acquirer, a return to operating leadership.
The best chairs in this context tend to come from one of three backgrounds. First are former CEOs of biopharma companies, ideally companies of similar size and stage, who have made the transition to board service and who understand the operating reality of a clinical-stage company without trying to relive their own CEO experience through someone else's company. Second are seasoned biopharma board members who have chaired multiple boards before and who are not in the role for the experience. Third — and most unusual — are former senior executives from large pharma who have moved into board service and who bring both the operating credibility and the network access that a small biopharma needs.
What they share, regardless of background, is the willingness to do work that no one will visibly thank them for. The chair's most important work is invisible: the difficult conversation with the CEO before the conversation has to happen at the board level, the recruitment call that surfaces a future director, the agenda revision that ensures the board confronts a question it would rather avoid. None of this generates the visible decisions that boards are usually credited for. The chair's effectiveness is most visible in the things that did not become problems.
The Lead Independent Director as a Bridge
For most clinical-stage biopharma companies, the realistic intermediate solution is not an independent chair but a lead independent director — either operating alongside a combined CEO-chair arrangement, or operating alongside an investor-chair while performing the substantive functions that the chair role cannot perform without independence.
The lead independent director model is borrowed from large-cap governance, where it serves as the structural counterweight to a CEO-chair arrangement. The lead independent director sets the agenda for executive sessions, serves as the primary channel for director-to-CEO communication on sensitive matters, and represents the independent directors as a group when their interests diverge from management or from significant shareholders.
In a small biopharma, the role can work, but it has structural challenges that are often underestimated. The first is authority. A lead independent director in a large-cap company derives authority partly from their position and partly from the institutional weight that comes with chairing committees or sitting on a board that has formal governance processes. A lead independent director in a small biopharma has neither of those scaffoldings. Their authority comes from their personal credibility and from the willingness of the CEO, the lead investor, and the other directors to defer to them on the matters within their purview. If any of those three actors does not buy in, the role becomes ceremonial.
The second challenge is selection. The lead independent director should be chosen by the independent directors as a group, not appointed by the CEO or the lead investor. In practice, in small boards where the social dynamics are intimate and the formal governance processes are thin, the role often defaults to whichever independent director has the most experience or the strongest personality, without an explicit selection process. This produces less legitimate authority than would result from an actual nomination and vote, even when the same person would have been selected either way.
The third challenge is scope. A lead independent director who tries to do everything that an independent chair would do will run into the limits of the role — they do not, structurally, control the board agenda or the meeting cadence. A lead independent director who interprets the role narrowly will not provide the governance counterweight that the role is supposed to provide. The right scope is in the middle, and finding it requires explicit conversation with the CEO and the rest of the board, not assumption.
Despite these challenges, the lead independent director model is often the practical answer for clinical-stage biopharma boards. It does not require finding an independent chair. It can be implemented within the existing board composition. And it can evolve, over time, toward a fuller independent chair model as the company matures and as the board's structure becomes more formal.
The Chair–CEO Relationship
Whatever the structure, the most consequential relationship on a small biopharma board is the relationship between the chair (or lead independent director) and the CEO. This relationship is not the same as the CEO's relationship with the lead investor, which is a financing relationship with governance dimensions. It is not the same as the CEO's relationship with the board as a whole, which is largely mediated through formal meetings. It is the relationship in which the CEO receives the candid input that the rest of the board, in its more formal posture, cannot provide.
The chair's role in this relationship is to be the person who tells the CEO what the CEO needs to hear, in a way the CEO can act on, before the issue becomes a board-level problem. This is harder than it sounds. The CEO of a clinical-stage biopharma is under sustained pressure — operating pressure, fundraising pressure, scientific pressure, often personal financial pressure. The chair's job is not to add to that pressure. It is to be a steady, credible source of perspective that helps the CEO navigate it.
The chair who does this well is rarely the chair who delivers dramatic feedback in board meetings. Most of the meaningful chair–CEO communication happens between meetings, often in informal settings — a phone call after the agenda has been circulated, a coffee before a difficult board discussion, a brief exchange about how a particular director is likely to react to a particular topic. This work is, again, invisible from the outside. It is also the work that, when it is not happening, produces the boards that are constantly surprised by problems they should have seen coming.
The CEO's role in this relationship is to actually use the chair as a sounding board, rather than treating the chair as another constituency to be managed. This requires a level of trust that takes time to build and that can be destroyed quickly. CEOs who treat their chair as a peer with whom they can think through hard problems get the benefit of a senior advisor who has skin in the game. CEOs who treat their chair as a critic to be neutralized get the dynamic that goes with that posture, which is rarely productive.
The structural protection for this relationship is the executive session. A board that meets in executive session at every regular meeting — without the CEO present — gives the chair and the independent directors the time and the space to discuss matters that cannot be discussed with the CEO in the room. The discipline of holding executive sessions regularly, rather than only when there is a problem, normalizes them. A board that holds an executive session only when something is wrong has telegraphed that something is wrong before the meeting begins.
The Chair During Transitions
The chair's role becomes most visible — and most consequential — during transitions. The most common transitions in a clinical-stage biopharma are CEO succession, the evaluation of a transaction, and the management of a crisis. In each of these, the chair is the person the board most depends on, and the work that has been done in normal times determines how well the transition is managed.
CEO succession in a clinical-stage company is rare but consequential. When it happens — because the founder-CEO is being replaced as the company matures, because the CEO has chosen to leave, because the board has lost confidence — the chair manages the process. The chair leads the search committee, manages the relationship with the outgoing CEO, presents candidates to the full board, and oversees the transition. In small companies that have not invested in a real chair role, this process is often run by an outside search firm with the lead investor as the primary client, which produces succession outcomes that are not always aligned with the company's long-term interest.
Transaction evaluation is the other transition where the chair's role becomes structural. When a company is approached by a potential acquirer or partner, the board's response is mediated through the chair. The chair manages the engagement with the acquirer's representatives, oversees the due diligence process, coordinates with the company's legal and financial advisors, and manages the dynamics within the board as different directors take different positions on the transaction. In transactions where the lead investor's interests diverge from the broader shareholder interest — which is a common scenario — the chair's independence becomes load-bearing.
Crisis management is the third transition. Clinical trial failures, regulatory setbacks, allegations of misconduct, sudden departures of senior executives — these moments demand the kind of steady, experienced leadership that the chair role is designed to provide. A chair who has built relationships across the board, who has the trust of the CEO, and who has earned the credibility of investors and advisors is positioned to lead through these moments. A chair who has not done this work is positioned mainly to react.
When the Role Should Evolve
The chair structure that fits a Series A biopharma is rarely the right structure for a company preparing to go public. As the company matures, the demands on the chair role grow, and the structural arrangements need to evolve to match.
In the earliest stages, a small board with the lead investor functioning as chair and an experienced independent director in a quasi-lead-independent role can work adequately. The board is small, the issues are concentrated around financing and early development, and the formal governance processes are thin enough that personal relationships substitute for institutional structure.
As the company progresses through clinical development and the board grows, the case for a more formal chair role strengthens. The board has more directors who do not know each other well, the financing dynamics become more complex, and the volume of substantive work increases to the point where someone needs to be explicitly responsible for managing the board as an institution. At this stage, many companies make the transition to a designated independent chair, or formally constitute the lead independent director role with a written charter rather than leaving it implicit.
By the time the company is preparing for a public listing, the chair structure should be one that can be sustained as a public company chair structure. Listing standards do not require an independent chair, but they require disclosure of the structure, and proxy advisors and institutional investors increasingly expect either an independent chair or a meaningful lead independent director role. A combined CEO-chair arrangement with a substantive lead independent director is defensible; an arrangement where the lead investor is the chair becomes harder to defend once the company is public, because the conflicts that were tolerable in a private company become visible to a wider set of shareholders.
The discipline of revisiting the chair structure as the company evolves — rather than letting the default arrangement persist by inertia — is one of the markers of a board that is being managed deliberately rather than by accident.
The Choice You Are Making
Most clinical-stage biopharma boards do not make a deliberate choice about their chair structure. The structure that emerges reflects the company's fundraising history, the personalities involved, and the path of least resistance from the initial Series A. This non-decision is, itself, a choice. It is a choice to accept whatever governance dynamic results, rather than to design a chair structure that fits the company's actual needs.
The boards that produce the best governance outcomes are the ones that have asked the question explicitly — who should chair this board, why, with what authority, and with what plan for evolution — and that have answered it with the same rigor they would apply to any other strategic decision. The chair role is not where governance happens, but it is where governance is either possible or impossible. Choosing it well is foundational. Allowing it to be chosen by default is not.
Lawrence Fine is CEO of AGCP Farmacêuticos and has direct biopharma board experience through Phase II clinical trials and successful exits.